No price history available.
Key financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | AUDm | 2 | 2 | 0 | 5 | 9 | 30 | N/A | N/A |
| Operating profit | AUDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | AUDm | -1 | -0 | -0 | -2 | -13 | 5 | N/A | N/A |
| EPS reported | AUD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | AUD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | AUD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | AUD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | AUDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | AUDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | AUDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | AUD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | AUD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Headquartered in Sydney, Australia, Bioxyne Limited is a life sciences and health company established in 1998. The firm dedicates itself to the research, development, marketing, and distribution of nutritional supplements and beauty products. Its operations are divided into wholesale and direct sales segments, reaching customers online, through partners, and directly across the United States and Asia. Bioxyne's diverse product line includes functional foods and cosmetic solutions, notably Progastrim for digestive and immune wellness, Progastrim plus Vitamin C for cold symptom relief, and proTract, specifically formulated for infant eczema (atopic dermatitis).
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Headquartered in Sydney, Australia, Bioxyne Limited is a life sciences and health company established in 1998. The firm dedicates itself to the research, development, marketing, and distribution of nutritional supplements and beauty products. Its operations are divided into wholesale and direct sales segments, reaching customers online, through partners, and directly across the United States and Asia. Bioxyne's diverse product line includes functional foods and cosmetic solutions, notably Progastrim for digestive and immune wellness, Progastrim plus Vitamin C for cold symptom relief, and proTract, specifically formulated for infant eczema (atopic dermatitis).